Hengsberger A, et al. Identifying items responsive to treatment and impairing QoL in people with epilepsy. EAN 2017, O2219.
Extra voordeel langere dosisinterval natalizumab: minder JCV-conversie
mei 2025 | Multipele Sclerose
jan 2024 | Neuro-vasculair
dec 2023 | Bewegingsstoornissen